Ratings RadNet, Inc.

Equities

RDNT

US7504911022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
48.4 ^USD	-0.92%		+4.04%	+39.20%

Apr. 18	RadNet Closes Term Loan, Revolving Credit Facility Refinancing Transaction	MT
Apr. 18	RadNet, Inc. Announces Closing of its Previously Announced Term Loan and Revolving Credit Facility Refinancing Transaction	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The company's profit outlook over the next few years is a strong asset.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

Low profitability weakens the company.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 93.08 times its estimated earnings per share for the ongoing year.
The valuation of the company is particularly high given the cash flows generated by its activity.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
RADNET, INC.	+39.20%	3.58B		C+
SONIC HEALTHCARE LIMITED	-16.58%	8.25B		B+
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.46B		B-
SYNLAB AG	-7.36%	2.46B		-
DR. LAL PATHLABS LIMITED	-8.95%	2.38B		B-
FLEURY S.A.	-19.01%	1.55B		A-
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.21B		C+
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.11B		B+
ADICON HOLDINGS LIMITED	-15.03%	1.03B	-	-
OPKO HEALTH, INC.	-16.56%	878M		C

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes